Recon: Lilly stockpiles $1.5B of weight loss pill in advance of FDA approval; FDA rejects Disc Medicine’s porphyria drug
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Lilly is stockpiling a significant amount of its weight loss pill, valued at $1.5 billion, in anticipation of FDA approval. Meanwhile, the FDA has rejected a porphyria drug submitted by Disc Medicine. The contrasting outcomes suggest differing regulatory decisions for the two pharmaceutical companies.